Loading
Latest filing published 27 Mar 2025 for Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.).
Jeffrey Mark Rowe is a declared insider of Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.), with filings sourced from SEDI. Between 21 April 2016 and 17 March 2025, the trades on record add up to 13 filings.
Every open-market trade on record is a purchase: 7 purchases worth €67k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2025, the count stands at 7 purchases and no sales.
In size, the median ticket on the buying side is €4,505. The 7 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The latest filing, published on 27 March 2025, reports a transaction in Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.). The latest purchase dates back some time: it was published 576 days ago, on 27 March 2025. Source: insider filings from SEDI. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations